DiObex, Inc. to Present at Merrill Lynch Global Healthcare Conference

DiObex, Inc., a privately held biotechnology company focused on the development of therapeutics to treat metabolic diseases, announced today that CEO David Cory will deliver a corporate presentation at the upcoming Merrill Lynch & Co, Inc. Global Pharmaceutical, Biotechnology and Medical Device Conference in New York, New York. The DiObex presentation will take place on Wednesday, Feb. 6 at 10:20 a.m. at the Grand Hyatt Hotel in the Broadway room.

About DiObex
DiObex, Inc. is a privately held San Francisco-based biotechnology company developing novel products for diabetes and metabolic diseases. DiObex has two product candidates in four mid-stage clinical development programs. DIO-901 (very low dose glucagon) is in development for the prevention of insulin- induced hypoglycemia in type 1 diabetes mellitus in an extended release subcutaneous formulation and as a convenient continuous subcutaneous infusion. DIO-901 has received Fast Track status from the FDA. DIO-902 (levdexketoconazole) is an oral, single enantiomer of ketoconazole that is a novel cortisol synthesis inhibitor in development for type 2 diabetes mellitus and diabetic nephropathy. Abnormalities in cortisol activity may play an important role in the development of metabolic syndrome, a constellation of conditions that place people at high risk for type 2 diabetes mellitus and cardiovascular disease. For more information, visit http://www.diobex.com.